Recursion focuses on diseases where there is a high unmet need – including aggressive cancers and rare diseases. The company is already seeing encouraging data for some of its clinical programs ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company integrating artificial intelligence (AI), machine learning, and high-throughput biology to accelerate drug ...

Recursion will also receive an additional $30 million upfront payment from Bayer to develop new treatments for chronic scar tissue, or fibrotic, diseases of the lung, kidneys and heart.

Recursion Pharmaceuticals dropped for a third straight day on Wednesday, slashing 6.29 percent to close at $4.77 apiece after investors mimicked the recent selling of three company executives.

Is Recursion Pharma a buy because of Nvidia’s endorsement? Indeed, Nvidia’s bet on Recursion is notable, but despite the stake and collaboration, the name isn’t without its fair share of risks.

According to data compiled by S&P Global Market Intelligence, Recursion Pharmaceuticals (NASDAQ: RXRX) stock was shedding more than 17% of its value week-to-date as of Thursday night.

Recursion Pharmaceuticals Inc is a trailblazer in the biotech industry, focusing on revolutionizing drug discovery by merging advancements in biology, chemistry, automation, data science, and ...

Explore RXRX's upcoming H2'25 trial updates for REC-4881 in familial adenomatous polyposis and REC-617.

The field of voice separation has made revolutionary progress in addressing the challenging 'cocktail party problem' with the ...